Amendment to Schedule 13D Filing for Kalaris Therapeutics, Inc.

This filing is an amendment to a Schedule 13D originally filed on March 25, 2025, by Samsara BioCapital, L.P. and related entities (collectively, "Reporting Persons"). The amendment, filed on December 22, 2025, supplements information regarding the ownership of Kalaris Therapeutics, Inc. common stock. On December 17, 2025, Samsara Opportunity Fund purchased 1,500,000 shares for $15 million in a private placement. The Reporting Persons collectively hold 11,448,081 shares directly held by Samsara LP, 1,500,000 shares held by Samsara Opportunity Fund, and Dr. Akkaraju holds 5,500 stock options. The total beneficial ownership attributed to Dr. Srinivas Akkaraju is 12,953,581 shares, representing 56.5% of the outstanding common stock. The filing also details a registration rights agreement entered into on December 17, 2025, obligating the issuer to register the resale of shares purchased in the private placement.